Study S001065

Effect of Liraglutide on Glycaemic Control in Subjects With Type 2 Diabetes.

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00154401
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 177
Start: 2005-01
Primary completion: 2005-10
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE

Registered primary outcomes

HbA1c [after 14 weeks treatment]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0023483	Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Jensen TM, Diabetes care	2015	Systematic review	PMID 25504028 DOI	registry reference RESULT:25504028
R0022665	Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Courrèges JP, Diabetic medicine : a journal of the British Diabetic Association	2008	Commentary	PMID 19183322 DOI	registry reference RESULT:19183322
R0022965	Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Vilsbøll T, Diabetic medicine : a journal of the British Diabetic Association	2008	Randomized trial	PMID 18201212 DOI	registry reference RESULT:18201212
R0024306	Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide. Horowitz M, Diabetes, obesity & metabolism	2008	Commentary	PMID 18435773 DOI	registry reference RESULT:18435773
R0023309	Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Vilsbøll T, Diabetes care	2007	Randomized trial	PMID 17372153 DOI	cites ClinicalTrials.gov:NCT00154401; registry reference RESULT:17372153